Spexin
An endogenous feeding-regulator peptide identified in 2007 — a younger entrant in the appetite-regulation peptide landscape.
Investigational compounds — read carefully
This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.
Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.
At a glance
A 14-amino-acid peptide acting on galanin receptors in appetite and metabolic regulation circuits. Circulating levels are reduced in obesity, suggesting a potential therapeutic axis through restoration or analog development.
- Class
- Endogenous galanin-receptor-binding peptide
- Sponsor
- Multiple academic research programs
- Stage
- Preclinical
- Lead use cases
- Obesity and metabolic dysfunction research
What it is
Spexin (also known as NPQ, neuropeptide Q) is a 14-amino-acid peptide initially identified through bioinformatic analysis of the C12ORF39 gene in 2007 (Mirabeau et al., Genome Res). It acts as an endogenous ligand for galanin receptors GalR2 and GalR3, with effects on appetite, feeding behavior, and lipid metabolism.
Current research status
Spexin remains primarily in preclinical research. Observational human studies have established that circulating spexin is reduced in obesity and metabolic syndrome, supporting the therapeutic-restoration hypothesis. Engineered spexin analogs and small-molecule GalR2/GalR3 agonists are in early development.
Mechanistic rationale
Through GalR2 and GalR3 activation, spexin reduces food intake and body weight in animal models, with effects partially complementary to the GLP-1 / GIP / amylin appetite-regulation axes. Distinct from those classes, spexin's effects involve hypothalamic feeding circuits and peripheral lipid metabolism through pathways distinct from the incretin biology dominating modern obesity pharmacology.
Available evidence
Discovery (Mirabeau et al., Genome Res 2007) — Spexin identified as an endogenous peptide with appetite-regulatory effects.[1]
Human observational studies — Multiple studies have documented reduced circulating spexin levels in obesity, T2D, and metabolic syndrome compared to lean controls.[2]
Animal models — Spexin administration reduces food intake and body weight in obese rodent models, with effects on lipid metabolism and insulin sensitivity.
Why it's interesting
Spexin represents a distinct mechanistic axis from the dominant incretin and amylin classes in obesity pharmacology. If long-acting spexin analogs or GalR2/GalR3 agonists can be engineered, they could provide a complementary therapeutic option — potentially useful in combination strategies or for patients who don't respond well to incretin therapy. The galanin receptor system has been an active drug-discovery target for decades, but mostly for neurological rather than metabolic indications.
Limitations & risks
Native spexin has a short plasma half-life, and engineered analogs are at early development stages. The galanin receptor system has broad CNS effects beyond appetite (mood, learning, pain modulation) — selectivity for the metabolic effects without producing CNS off-target effects is part of the engineering challenge. Translation from rodent obesity models to human clinical effects has not yet been characterized.
Community discussion notes
Limited biohacker-community awareness given the early-stage development. Of considerable academic interest as an addition to the endogenous appetite-regulation peptide landscape alongside leptin, ghrelin, GDF15, and PYY.
The takeaway
Spexin is a younger entry in the long-running effort to characterize the endogenous regulators of appetite and metabolism. The therapeutic translation distance is significant — likely 5+ years from any clinical application — but the underlying biology is interesting and the receptor pharmacology (GalR2/GalR3) provides a potential development pathway.
References
- Mirabeau O, et al. Identification of novel peptide hormones in the human proteome by hidden Markov model screening. Genome Res. 2007;17(3):320-327. https://pubmed.ncbi.nlm.nih.gov/17284679/
- Walewski JL, et al. Spexin is a novel human peptide that reduces adipocyte uptake of long chain fatty acids and causes weight loss in rodents with diet-induced obesity. Obesity. 2014;22(7):1643-1652. https://pubmed.ncbi.nlm.nih.gov/24550067/